United Therapeutics Corporation
A maker of medicines for rare lung conditions such as pulmonary arterial hypertension, sold under brands like Remodulin and Tyvaso. Founder Martine Rothblatt launched the company in 1996 after her young daughter was diagnosed with the disease, turning a personal fight into a career. The firm is also known for a futuristic goal: gene-edited pig organs for human transplants, an approach that has made it a familiar name in xenotransplantation.
Granted 1.20M · Sold 1.15M
Granted 223.6K · Sold 206.9K
Granted 604.2K · Sold 570.8K
Granted 9.5K · Sold 9.5K
Granted 417.7K · Sold 398.3K
Granted 4.9K · Sold 4.9K
Granted 6.0K · Sold 6.0K
Sold 445
Sold 2.6K
Granted 8.3K · Sold 8.3K
Granted 4.9K · Sold 4.9K
Sold 1.1K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Rothblatt Martine AChairperson & CEO, Director · 1371 transactions | +6682.6% | 49.6K | 1.20M | — | 1.15M |
| Mahon Paul AEVP & GENERAL COUNSEL · 204 transactions | +4.8% | 45.2K | 223.6K | — | 206.9K |
| Benkowitz MichaelPRESIDENT AND COO · 286 transactions | +718.5% | 36.5K | 604.2K | — | 570.8K |
| Thompson Tommy GDirector · 10 transactions | +7.1% | 30.3K | 9.5K | — | 9.5K |
| Edgemond JamesCFO AND TREASURER · 424 transactions | +214.2% | 25.5K | 417.7K | — | 398.3K |
| Kurzweil RayDirector · 2 transactions | +38.8% | 17.6K | 4.9K | — | 4.9K |
| Sullivan Louis WDirector · 4 transactions | +0.5% | 6.4K | 6.0K | — | 6.0K |
| Mesa NildaDirector · 2 transactions | -8.1% | 5.0K | — | — | 445 |
| Olian Judy D.Director · 5 transactions | -38% | 4.2K | — | — | 2.6K |
| Causey ChristopherDirector · 17 transactions | -13.9% | 4.2K | 8.3K | — | 8.3K |
| Patusky ChristopherDirector · 6 transactions | 0% | 2.6K | 4.9K | — | 4.9K |
| Malcolm JanDirector · 9 transactions | -89.8% | 125 | — | — | 1.1K |
Select a row to see that insider’s individual transactions. Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last year: -2.36M shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.